Panitumumab: A guide to its use in metastatic colorectal cancer

被引：0

作者：

Gillian M. Keating

机构：

[1] Adis, North Shore 0754, Auckland, 41 Centorian Drive, Private Bag 65901, Mairangi Bay

来源：

Drugs & Therapy Perspectives | 2012年 / 28卷 / 7期

关键词：

Adis-Clinical-Q-and-A; Colorectal-cancer; Panitumumab;

D O I：

10.2165/11208660-000000000-00000

中图分类号：

学科分类号：

摘要：

Panitumumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, prolongs progression-free survival in patients with metastatic colorectal cancer and wild-type KRAS tumours when administered intravenously in combination with FOLFOX as first-line treatment, in combination with FOLFIRI as second-line treatment, or as monotherapy in chemotherapy-refractory disease. It has an acceptable tolerability profile, is associated with the skin-related toxicities characteristic of EGFR inhibitors and appears to have a low risk of immunogenicity. Adis © 2012 Springer International Publishing AG. All rights reserved.

引用

页码：6 / 9

页数：3

共 12 条

[1]

Center M.M., Jemal A., Smith R.A., Et al., Worldwide variations in colorectal cancer, CA. Cancer J. Clin., 59, 6, pp. 366-378, (2009)

[2]

Mancl E.E., Kolesar J.M., Vermeulen L.C., Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors, Am. J. Health Syst. Pharm., 66, 23, pp. 2105-2112, (2009)

[3]

Keating G.M., Panitumumab: A review of its use in metastatic colorectal cancer, Drugs, 70, 8, pp. 1059-1078, (2010)

[4]

Banck M.S., Grothey A., Biomarkers of resistance to epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer, Clin Cancer Res, 15, 24, pp. 7492-7501, (2009)

[5]

London: European Medicines Agency, (2011)

[6]

CA: Amgen Inc., (2011)

[7]

Douillard J.Y., Siena S., Cassidy J., Et al., Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus Folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The prime study, J. Clin. Oncol., 28, 31, pp. 4697-4705, (2010)

[8]

Peeters M., Price T.J., Cervantes A., Et al., Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer, J. Clin. Oncol., 28, 31, pp. 4706-4713, (2010)

[9]

Van Cutsem E., Peeters M., Siena S., Et al., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer, J. Clin. Oncol., 25, 13, pp. 1658-1664, (2007)

[10]

Amado R.G., Wolf M., Peeters M., Et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J. Clin. Oncol., 26, 10, pp. 1626-1634, (2008)

← 1 2 →